Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04084080 · ClinicalTrials.gov registry record · Phase 3
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
A Phase 3 study of Sickle Cell Disease, sponsored by University of Pittsburgh.
- Active
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 20
- Study locations
NCT04084080: Active Phase 3 study of Sickle Cell Disease, sponsored by University of Pittsburgh.
NCT04084080 is a Phase 3 study of Sickle Cell Disease that is active but no longer recruiting, run by University of Pittsburgh. The registered enrollment target is 173 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04084080, a Phase 3 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by University of Pittsburgh.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 20
- Study locations
Study Summary
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Primary Outcome
The efficacy of the intervention will be measured by comparing the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 13 months between groups.
Conditions Studied
Interventions
- OTHER Standard of care
- BIOLOGICAL Red Blood Cell
Study Locations (20)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Atrium Health - Charlotte
- Duke University - Durham
- East Carolina University - Greenville
Maryland
- University of Maryland - Baltimore
- Johns Hopkins University - Baltimore
New York
- Icahn School of Medicine at Mount Sinai - New York
- Montefiore Medical Center - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Ohio State University - Columbus
Alabama
- University of Alabama - Tuscaloosa
California
- UCSF Benioff Children's Hospital Oakland - Oakland
District of Columbia
- Howard University Center for Sickle Cell Disease - Washington D.C.
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 3 |
What the registry record for NCT04084080 still lists
NCT04084080 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.
NCT04084080 names 20 study sites across 14 states, led by North Carolina, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT04084080 about?
NCT04084080 is a clinical study titled "Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)". The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening...
What is the current status of trial NCT04084080?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2020-02-26. Estimated completion is 2026-05-31.
What conditions does trial NCT04084080 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT04084080?
The interventions under investigation include: Standard of care (OTHER), Red Blood Cell (BIOLOGICAL).
Who is sponsoring clinical trial NCT04084080?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04084080 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04084080's enrollment target sits among peer trials
173 40th of 213 higher than 174 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITING · Phase 3
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
RECRUITING · Phase 3
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RECRUITING · Phase 3
-
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
RECRUITING · Phase 3
-
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI